ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,086.49
0.61%
Dow Jones
45,014.04
0.69%
US Dollar vs MXN
20.29965
-0.10%
Brent Oil
72.385
-1.66%
Bitcoin
98,142.56
2.27%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Europa
  5. EU

  6. Abivax (ABVX) Cotización

Abivax

Abivax (ABVX)

Abivax SA
8.06
0.40
(5.22%)
Cerrado 04 Diciembre 10:30AM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
8.06
Postura de Compra
7.86
Postura de Venta
8.18
Volume Operado de la Acción
35,143
7.71 Rango del Día 8.24
7.59 Rango de 52 semanas 15.42
Capitalización de Mercado [m]
507.206M
Precio Anterior
7.66
Precio de Apertura
7.71
Hora
1
@
8.06
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
21,252
Acciones en circulación
62,928,818
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-3.43
Beneficio por acción (BPA)
-2.35
turnover
4.62M
Beneficio neto
-147.74M

Acerca de Abivax

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.abivax.com
Sede
Paris, Paris, Fra
Fundado
-
Abivax is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ABVX. The last closing price for Abivax was 7.66 €. Over the last year, Abivax shares have traded in a share price range of 7.59 € to 15.42 €.

Abivax currently has 62,928,818 shares in issue. The market capitalisation of Abivax is 482.03 € million. Abivax has a price to earnings ratio (PE ratio) of -3.43.

ABVX Últimas noticias

Más noticias

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the...

19 Noviembre 2024
GlobeNewswire Inc.

Abivax presents third quarter 2024 key financial information

Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the...

14 Noviembre 2024
GlobeNewswire Inc.

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and...

13 Noviembre 2024
GlobeNewswire Inc.

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00...

07 Octubre 2024
GlobeNewswire Inc.

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris:...

03 Octubre 2024
GlobeNewswire Inc.

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients...

03 Octubre 2024
GlobeNewswire Inc.

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy...

26 Septiembre 2024
GlobeNewswire Inc.

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease...

25 Septiembre 2024
GlobeNewswire Inc.

Abivax presents first-half 2024 financial results

Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA (Euronext...

09 Septiembre 2024
GlobeNewswire Inc.

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the...

06 Agosto 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.384.947916666677.688.247.59224937.79593847DE
4-1.45-15.2471083079.51107.59237138.50461886DE
12-2.68-24.953445065210.7410.867.59212528.98320095DE
26-4.14-33.934426229512.213.587.591984910.33202574DE
52-1.39-14.7089947099.4515.427.592555611.38398782DE
156-14.59-64.415011037522.65295.63158512.15371008DE
260-5.24-39.398496240613.336.75.63289316.73332802DE

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ALCOXNicox SA
0.2895 €
(32.49%)
1.34M
ALGTRGroupe Tera SA
2.40 €
(28.34%)
410
ALSAFSAFE
0.086 €
(23.92%)
80.01k
ALAGOEPango SA
0.1062 €
(16.45%)
2.54M
MLCMIScemi
3.96 €
(14.45%)
4
ALCYBCybergun
0.0001 €
(-50.00%)
2.68M
ALTMENoxxon Pharma NV
0.0896 €
(-42.34%)
4.69M
GNROGeNeuro SA
0.0428 €
(-34.56%)
1.05k
ALEUPEuroplasma
0.047 €
(-32.86%)
2.61M
ATOAtos SE
0.339 €
(-31.52%)
14.65M
ALNEVNeovacs
0.0003 €
(0.00%)
52.59M
BCPBanco Comercial Portugues SA
0.4469 €
(0.27%)
34.35M
ATOAtos SE
0.339 €
(-31.52%)
14.65M
ORAOrange.
9.414 €
(-3.01%)
14.62M
ALHPIHopium SA
0.0089 €
(3.49%)
11.09M

Discusión

Ver feed completo
Bull_Dolphin Bull_Dolphin 2 minutos hace
Pete on Carl Higgbie, "I am not deopping out!"

Go Pete!
boo boo boo boo 2 minutos hace
Narcissism - look it up. I even spelled it for you.
Steady_T Steady_T 2 minutos hace
That is a nice idea but it doesn't do well in the face of reality.
Clinical trials site doesn't get updated frequently and then after a significant event in the trial.

The clinical trials site has a last update date. Any events since that date are officially unknown unless ther
AVXL
fwb fwb 3 minutos hace
Agreed.
I hear that about PLTR from time to time;
They wish they had picked up some shares of PLTR when it was Treading under $20,00
PLTR
stink stack stink stack 3 minutos hace
I like you! A good sence of humor is what it takes to endure the f*#ckings We have taken to get that Golden goose ticket to the promise land. GLTU
FNMA
m$teamworkotc m$teamworkotc 4 minutos hace
very bullish close 0011 on strong buying....with a cool billion in assets and low to no debt HMBL is again in position to have another TSNP like run...
HMBL
DrRocker57 DrRocker57 4 minutos hace
Have others received their proxies/voting materials? I have yet to hear or receive anything. I will be voting no with my 28k shares though I am doubtful it will make any difference. This has been a well orchestrated thievery and I hope legal avenues will be pursued to defend shareholders.
CDMO
Nelson2 Nelson2 4 minutos hace
Impressive and mature reply
I am a sports trend bettor. My friends pay no attention to it.
But I believe my results are better because of it

GLTU
DEFTF
arcav717 arcav717 5 minutos hace
TRADING AT.10 AFTER MKT.
KBLB
DjScottyT DjScottyT 5 minutos hace
What’s there to talk about? You act like this stock did something. It’s still sub, sub zero. What have they accomplished that has you so happy? 🤣🤣🤣🤣
TSOI
Inspector Clouseau Inspector Clouseau 7 minutos hace
I like what I saw and heard,he said they have enough cash on hand for the year so if everything goes well it should shoot up and even if it only hits a dollar in the next few months that's 10 times your money which is ok with me.The bridge loan will be when they have customers lined up so it should
KBLB
Hi_Lo Hi_Lo 7 minutos hace
How did your investment in GVS* go after pumping that stock for three years and 13,917 posts?

I see you don't show your face there anymore after you took MASSIVE losses on that dumpster fire.

You'll do no better here with this CRTG junk.

LOL!!!
CRTG
budfoxfun budfoxfun 8 minutos hace
Collaboration of media with QVC and HSN (Home Shopping Network) with the support of Mann Media and Worldwide TV Products has the potential to generate millions of dollars in revenue, further reinforcing SGTM's commitment to sustainable growth.
SGTM
LowFloatLopes LowFloatLopes 8 minutos hace
lol In all honesty, I think it happens late this evening or early early early in the morning after midnight
BTCUSD
EisMCA2 EisMCA2 8 minutos hace
Here is the link to the video on the KBLB YouTube page instead of MarketNews.
Plenty of good news.

https://youtu.be/lip5ubLT1X0?si=e8roRePj-apOzU5k https://youtu.be/lip5ubLT1X0?si=e8roRePj-apOzU5k

Go KBLB!
MCA
KBLB
space~farm space~farm 8 minutos hace
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30438-4/fulltext

Enjoy life with your tinfoil hat :)
NWBO
peafunke peafunke 8 minutos hace
I don't believe they have enough voting rights / shares.  He ones >51%
TPTW
Renee Renee 9 minutos hace
IDEX changed to IDEXQ, bankruptcy.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
IDEX
budfoxfun budfoxfun 9 minutos hace
Sustainable Green Team (OTCQX:SGTM)
CEO Tony Raynor will discuss the company's mission and strategies for sustainability and environmental responsibility, positioning the team as a leader in the green industry.
Website: www.thesustainablegreenteam.com
SGTM
blackhawks blackhawks 9 minutos hace
You don't even know the meaning of the words you use.

INCITEMENT is one of the unprotected actions and Trump did incite the INSURRECTION, lawless action, against the Capitol and its proceedings........to certify the election.

speech “directed at inciting or producing im
nilremerlin nilremerlin 10 minutos hace
50 dma now up to .42 above the 200 dma, further confirming the integrity of the Golden Cross.
VWAP 3.46 US, Down today.
Close $3.48 US, Down today.
Volume was less than the average today.
$3 US VWAP close was achieved on
10/29/24.
Above $3 US VWAP close achi
HITI
BIOCHEMUP BIOCHEMUP 10 minutos hace
Retracement done imo.
RKLB
subslover subslover 10 minutos hace
$4.29 on this === On December 4, 2024, Nasdaq notified the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rules for continued listing.
PRFX
northam43 northam43 11 minutos hace
Report #6 SPX All Cycles Chart.

https://investorshub.advfn.com/uimage/uploads/2024/12/4/logl[6_All_Cycles_Chart.png

Su Consulta Reciente

EU
ABVX
Abivax
BIT
UB1X6Y
UniCredit Bank
BIT
UC5658
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados